Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.

Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D.

Cancer Immunol Immunother. 2019 Jun;68(6):917-926. doi: 10.1007/s00262-019-02321-z. Epub 2019 Mar 15.


Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study.

Mendoza TR, Kehl KL, Bamidele O, Williams LA, Shi Q, Cleeland CS, Simon G.

Support Care Cancer. 2019 Jan 19. doi: 10.1007/s00520-018-4632-0. [Epub ahead of print]


Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.

Kehl KL, Lathan CS, Johnson BE, Schrag D.

J Natl Cancer Inst. 2019 Apr 1;111(4):431-434. doi: 10.1093/jnci/djy202.


Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.

Kehl KL, Niu J, Chavez-MacGregor M, Giordano SH.

Cancer. 2018 Dec 15;124(24):4685-4691. doi: 10.1002/cncr.31760. Epub 2018 Sep 28.


Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS.

Clin Cancer Res. 2017 Jul 20. doi: 10.1158/1078-0432.CCR-16-3027. [Epub ahead of print]


Access to Accredited Cancer Hospitals Within Federal Exchange Plans Under the Affordable Care Act.

Kehl KL, Liao KP, Krause TM, Giordano SH.

J Clin Oncol. 2017 Feb 20;35(6):645-651. doi: 10.1200/JCO.2016.69.9835. Epub 2017 Jan 9. Erratum in: J Clin Oncol. 2017 Jun 20;35(18):2100.


Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.

Shen C, Kehl KL, Zhao B, Simon GR, Zhou S, Giordano SH.

Clin Lung Cancer. 2017 Jul;18(4):e233-e241. doi: 10.1016/j.cllc.2016.11.002. Epub 2016 Nov 11.


Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer.

Kehl KL, Shen C, Litton JK, Arun B, Giordano SH.

Breast Cancer Res Treat. 2016 Aug;159(1):201. No abstract available.


BRCA1 and BRCA2 Testing Among Young Breast Cancer Survivors.

Kehl KL, Giordano SH.

JAMA Oncol. 2016 May 1;2(5):688-9. doi: 10.1001/jamaoncol.2016.0976. No abstract available.


Rates of BRCA1/2 mutation testing among young survivors of breast cancer.

Kehl KL, Shen C, Litton JK, Arun B, Giordano SH.

Breast Cancer Res Treat. 2016 Jan;155(1):165-73. doi: 10.1007/s10549-015-3658-y. Epub 2015 Dec 26. Erratum in: Breast Cancer Res Treat. 2016 Aug;159(1):201.


Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care: Shared Decision Making in Cancer Care.

Kehl KL, Landrum MB, Arora NK, Ganz PA, van Ryn M, Mack JW, Keating NL.

JAMA Oncol. 2015 Apr;1(1):50-8. doi: 10.1001/jamaoncol.2014.112.


Tumor board participation among physicians caring for patients with lung or colorectal cancer.

Kehl KL, Landrum MB, Kahn KL, Gray SW, Chen AB, Keating NL.

J Oncol Pract. 2015 May;11(3):e267-78. doi: 10.1200/JOP.2015.003673. Epub 2015 Apr 28.


Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer.

Kehl KL, Lamont EB, McNeil BJ, Bozeman SR, Kelley MJ, Keating NL.

J Geriatr Oncol. 2015 May;6(3):202-10. doi: 10.1016/j.jgo.2015.01.005. Epub 2015 Feb 3.


Oncologists' experiences with drug shortages.

Kehl KL, Gray SW, Kim B, Kahn KL, Haggstrom D, Roudier M, Keating NL.

J Oncol Pract. 2015 Mar;11(2):e154-62. doi: 10.1200/JOP.2014.000380. Epub 2014 Dec 30.


Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer.

Kehl KL, Arora NK, Schrag D, Ayanian JZ, Clauser SB, Klabunde CN, Kahn KL, Fletcher RH, Keating NL.

J Natl Cancer Inst. 2014 Sep 13;106(10). pii: dju216. doi: 10.1093/jnci/dju216. Print 2014 Oct.

Supplemental Content

Support Center